Compare · ABSI vs PPD
ABSI vs PPD
Side-by-side comparison of Absci Corporation (ABSI) and PPD, Inc. (PPD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABSI and PPD operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- PPD is the larger of the two at $16.64B, about 10.4x ABSI ($1.59B).
- ABSI has hit the wire 9 times in the past 4 weeks while PPD has been quiet.
- ABSI has more recent analyst coverage (21 ratings vs 1 for PPD).
- Company
- Absci Corporation
- PPD, Inc.
- Price
- $10.24+0.10%
- $47.29-0.07%
- Market cap
- $1.59B
- $16.64B
- 1M return
- +57.54%
- -
- 1Y return
- +299.22%
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2020
- News (4w)
- 9
- 0
- Recent ratings
- 21
- 1
Absci Corporation
Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. The company was founded in 2011 and is headquartered in Vancouver, Washington.
PPD, Inc.
PPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company has a collaboration with Science 37 to design, build, test, implement, and execute digital trials using Science 37's DCT SaaS-based technology platform. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina.
Latest ABSI
- Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026
- Director Szela Mary T bought $148,866 worth of shares (12,900 units at $11.54), increasing direct ownership by 154% to 21,300 units (SEC Form 4)
- The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
- Chief Executive Officer Mcclain Sean covered exercise/tax liability with 59,896 shares, decreasing direct ownership by 0.69% to 8,655,555 units (SEC Form 4) (for tax liability)
- SEC Form 8-K filed by Absci Corporation
- SEC Form 424B5 filed by Absci Corporation
- Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors
- Absci Corporation filed SEC Form 8-K: Financial Statements and Exhibits
- Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)
- The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It
Latest PPD
- InnoCare Pharma Goes Back to Funding Trough With STAR Market Listing
- Saama Appoints Scott Rogers as Company's Chief Financial Officer
- SEC Form 15-12B filed by PPD, Inc.
- SEC Form 4: Carlyle Group Inc. disposed of $2,646,829,818 worth of shares (55,722,733 units at $47.50)
- SEC Form SC 13G filed by PPD, Inc.
- SEC Form 4: H&F Corporate Investors Viii, Ltd. sold $6,309,960,135 worth of shares (132,841,266 units at $47.50)
- SEC Form 4: H&F Corporate Investors Vii, Ltd. sold $6,309,960,135 worth of shares (132,841,266 units at $47.50)
- SEC Form 4: Johnston David Michael returned $1,681,832 worth of shares to the company (60,929 units at $27.60) and was granted 25,522 shares, closing all direct ownership in the company
- SEC Form 4: Hill Colin returned $775,675 worth of shares to the company (16,330 units at $47.50), closing all direct ownership in the company
- SEC Form 4: Kaucic Karen returned $398,620 worth of shares to the company (31,496 units at $12.66) and was granted 23,104 shares, closing all direct ownership in the company